Webinar | November 13, 2023

Achieving Flexibility And Scalability In Cell Therapy Manufacturing Through Optimized Cell Isolation And Activation

T cells GettyImages-956478348

Learn about a first-of-its-kind platform technology that enables isolation and activation of T cells in one step with a key differentiator: an active release mechanism for clinical trial or commercial manufacturing. The Gibco™ CTS™ Detachable Dynabeads™ CD3/CD28 Kit possesses a proprietary active release mechanism that enables the intentional early release of Dynabeads from the cells before the naturally occurring release at day 4 or 5. Conjugated to highly specific, single-domain VHH antibodies that target specific clusters of differentiation markers, the performance exhibits consistent and optimal isolation, activation, and purity of target T cell populations while addressing the biological variability that cell therapy manufacturers are facing.

In this webinar you will learn about:

  • How the active detachment of Dynabeads from target cells at any time allows users to add flexibility and scalability to their process
  • How to maintain desired cell phenotypes
  • Suitability for both autologous and allogeneic processes
access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene

Thermo Fisher Scientific Bioproduction